| Autor: |
Shang, Li, Dong, Liling, Huang, Xinying, Wang, Tianyi, Mao, Chenhui, Li, Jie, Wang, Jie, Liu, Caiyan, Gao, Jing |
| Zdroj: |
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2023 Supplement 15, Vol. 19, p1-2, 2p |
| Abstrakt: |
Background: Apolipoprotein‐E (APOE) ε4 is a major genetic risk factor for Alzheimer's disease (AD). Current studies, which mainly based on the clinical diagnosis rather than biomarkers, come to inconsistent conclusions regarding the effect of APOE ε4 homozygotes (APOE ε4/ε4) on cerebrospinal fluid (CSF) biomarkers of AD. Additionally, few studies have explored the effect of APOE ε4/ε4 on plasma biomarkers. Therefore, we aimed to investigate the effect of APOE ε4/ε4 on CSF and plasma biomarkers in dementia and biomarker diagnosed AD. Method: A total of 297 patients were enrolled. They were classified into Alzheimer's continuum, AD and non‐AD according to CSF biomarkers and/or β amyloid PET results. Plasma Aβ40, Aβ42, glial fibrillary acidic protein (GFAP), neurofilament light chain (NFL) and P‐tau181 were quantified in 144 of the total population using an ultra‐sensitive Simoa technology. We analyzed the effect of APOE ε4/ε4 on CSF and plasma biomarkers in dementia and biomarker‐diagnosed AD. Result: Based on the biomarker diagnostic criteria, 169 participants were diagnosed with Alzheimer's continuum, 120 patients with AD and 128 individuals with non‐AD. The APOE ε4/ε4 frequencies were 14.2% (17/120) in AD, 11.8% (20/169) in Alzheimer's continuum and 0.8% (1/128) in non‐AD. Only CSF Aβ42 was shown to be decreased in APOE ε4/ε4 carriers than in non‐carriers for patients with AD (P = 0.024). As well, we did not find any effect of APOE ε4 on plasma biomarkers of AD and non‐AD. Interestingly, we found that in non‐AD patients, APOE ε4 carriers had lower CSF Aβ42 (P = 0.018) and higher T‐tau/Aβ42 ratios (P<0.001) and P‐tau181/Aβ42 ratios (P = 0.002) than non‐carriers. Conclusion: Our data confirmed APOE ɛ4/ɛ4 was most common in biomarker diagnosed AD. The APOE ɛ4/ɛ4 had an effect on CSF levels of Aβ42 but not tau for AD and non‐AD, suggesting that APOE ɛ4/ɛ4 affected the Aβ metabolism of both. APOE ε4/ɛ4 had no effect on plasma biomarkers of AD and non‐AD. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
